Ascenta Raises $50 Million

Ascenta Therapeutics Inc., a San Diego-based cancer drug company, has raised $50 million in Series C funding commitments. The initial $30 million has already been called down, while the remainder will come once the company satisfies certain milestones. Perseus led the deal, and was joined by return backers Domain Associates, Sofinnova Ventures, Enterprise Partners Venture Capital, Scale Venture Partners and U.S. Venture Partners. Ascenta previously raised $35.5 million in VC funding.